Bristol-Myers Squibb Co. (BMY)

42.75
0.02 0.05
NYSE : Health Technology
Prev Close 42.77
Open 42.81
Day Low/High 42.48 / 42.88
52 Wk Low/High 42.72 / 63.69
Volume 4.32M
Avg Volume 12.80M
Exchange NYSE
Shares Outstanding 1.64B
Market Cap 70.88B
EPS 3.00
P/E Ratio 13.80
Div & Yield 1.64 (3.68%)

Latest News

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Despite the financial positivity, many analysts warn the deal could have hiccups ahead.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

Bristol-Myers Continues to Show Bottoming Price Action on the Charts

Bristol-Myers Continues to Show Bottoming Price Action on the Charts

Let's check out the charts of BMY.

IPO Gives Chinese Couple a 'Hansoh' Sum

IPO Gives Chinese Couple a 'Hansoh' Sum

The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Jim Cramer: What Do Trump's Whims Per Share Look Like?

Jim Cramer: What Do Trump's Whims Per Share Look Like?

What happened to the business president? I think what happened is that the polls are showing that whatever the president is doing is working.

Bristol-Myers Squibb: A Long Idea for Aggressive Traders Only

Bristol-Myers Squibb: A Long Idea for Aggressive Traders Only

BMY is not 'out of the woods' yet, but aggressive traders could probe the long side here.

Jim Cramer: It Isn't a Slowdown That I Fear, It's a Tweet

Jim Cramer: It Isn't a Slowdown That I Fear, It's a Tweet

This is the first time I can ever recall when a president is so attuned to the market that he will bend to its wishes.

Jim Cramer: What to Buy and What to Avoid on Trump's Latest China Tweet

Jim Cramer: What to Buy and What to Avoid on Trump's Latest China Tweet

As usual, the stocks that bounce back first are the tech stocks with little Chinese exposure and the consumer packaged goods that just demonstrated good numbers.

Jim Cramer: My Bet's on the 'Ladies' in This Year's Draft

Jim Cramer: My Bet's on the 'Ladies' in This Year's Draft

Analyzing this year's stock draft contest and individual stock-picking vs. indexing.

Keep Your Eye on the Oncology Sector Among Biotech Stocks

Keep Your Eye on the Oncology Sector Among Biotech Stocks

The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.

Seattle Genetics Struggles as Other Biotech Stocks Rise

Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...

A Solid Start for the Market

We are currently in process of restoring my access that is blocking me from seeing or commenting on the Daily Diary. We hope to have the problem resolved soon. Our apologies while getting the issue resolved. The market is off to a solid start this F...

Future Brightens for 2 Small Biotech Stocks

Future Brightens for 2 Small Biotech Stocks

The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

David Tepper's Appaloosa LP renews calls for changes at the top.

I Like the Long Side of Bristol-Myers Squibb

I Like the Long Side of Bristol-Myers Squibb

Let's see what the charts and indicators look like.

5 Attractive Ways to Invest in Oncology

5 Attractive Ways to Invest in Oncology

Experts offer their top stock ideas in oncology detection and treatment.

Caterpillar's 'High-Water Mark' Comment in 2018 Puts Finer Focus on 2019 Outlook

Caterpillar's 'High-Water Mark' Comment in 2018 Puts Finer Focus on 2019 Outlook

Management commentary from CAT is key on Monday.

What Fools We All Have Become, and Buying Lam Research: Market Recon

What Fools We All Have Become, and Buying Lam Research: Market Recon

Replacing fear with pragmatism, that is our goal.

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

These themes are working despite the turmoil in Washington and slowing global growth.

Jim Cramer: What Are We to Make of Today's Market Decline?

Jim Cramer: What Are We to Make of Today's Market Decline?

Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?

Real Money Post-Industrial Average Records 7% Gain So Far in 2019

Real Money Post-Industrial Average Records 7% Gain So Far in 2019

The RMPIA is once again outpacing the S&P 500, Dow Jones Industrial Average and the Nasdaq Composite Index.

Jim Cramer: There's a Ton More Deals in the Pipe

Jim Cramer: There's a Ton More Deals in the Pipe

Deals that simply were unworkable four months ago because of price are now being done with alacrity.

Goldman's Gold Standard in M&A Bolsters Outlook for 2019

Goldman's Gold Standard in M&A Bolsters Outlook for 2019

Goldman is top of the heap for takeovers.